AD/PD 2025: Buntanetap shows promise in early Parkinson's with mild dementia [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
six-month, randomised, double-blind, placebo-controlled Phase III clinical trial investigating the efficacy, safety, and tolerability of 10mg and 20mg doses of buntanetap or placebo in patients with early PD. The presentation highlighted the potential of buntanetap in improving motor and nonmotor functions in patients with PD and mild dementia. At the AD/PD 2025 'Advances in PD Treatment' presentation, Annovis Bio announced that while buntanetap demonstrated statistically significant improvements in every primary and secondary endpoint in the per-protocol population, buntanetap failed to reach the primary endpoint in the total intention-to-treat population. Buntanetap did not demonstrate a statistically significant change from baseline to Month 6 in Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS) Part II score in this patient population. However, buntanetap showed promise in preventing cognitive decline, as the Mini Mental State Examination (M
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients [Yahoo! Finance]Yahoo! Finance
- Annovis Announces Open-Label Extension Study for Parkinson's Disease PatientsGlobeNewswire
- Annovis to Host Corporate Update Webinar on January 28, 2026GlobeNewswire
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study GroupGlobeNewswire
- Annovis Announces Two Presentations at the CTAD 2025 ConferenceGlobeNewswire
ANVS
Analyst Actions
- 9/30/25 - Canaccord Genuity
ANVS
Sec Filings
- 12/8/25 - Form 4
- 11/25/25 - Form 4/A
- 11/25/25 - Form 4
- ANVS's page on the SEC website